Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash
Aclarion (NASDAQ: ACON) announced that its Nociscan product is featured in the RSNA Edition of Siemens Healthineers magazine, MAGNETOM Flash. The article showcases how physicians incorporate Nociscan into their clinical practices for chronic low back pain patients. Nociscan is the first evidence-supported SaaS platform that helps physicians noninvasively distinguish between painful and nonpainful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain. The feature will be highlighted at the RSNA annual meeting from December 1-4, 2024, and is expected to serve as a valuable reference for the medical community.
Aclarion (NASDAQ: ACON) ha annunciato che il suo prodotto Nociscan è presente nell'Edizione RSNA della rivista Siemens Healthineers, MAGNETOM Flash. L'articolo illustra come i medici integrano Nociscan nelle loro pratiche cliniche per pazienti con dolore cronico alla schiena. Nociscan è la prima piattaforma SaaS supportata da evidenze che aiuta i medici a distinguere in modo non invasivo tra dischi dolorosi e non dolorosi nella colonna lombare, quantificando i biomarcatori chimici associati al dolore del disco. La caratteristica sarà evidenziata alla riunione annuale RSNA che si terrà dal 1 al 4 dicembre 2024 e si prevede che sarà un prezioso riferimento per la comunità medica.
Aclarion (NASDAQ: ACON) anunció que su producto Nociscan será presentado en la Edición RSNA de la revista Siemens Healthineers, MAGNETOM Flash. El artículo muestra cómo los médicos incorporan Nociscan en sus prácticas clínicas para pacientes con dolor lumbar crónico. Nociscan es la primera plataforma SaaS respaldada por evidencia que ayuda a los médicos a distinguir de manera no invasiva entre discos dolorosos y no dolorosos en la columna lumbar al cuantificar biomarcadores químicos asociados con el dolor de disco. Esta característica se destacará en la reunión anual de RSNA del 1 al 4 de diciembre de 2024 y se espera que sirva como una referencia valiosa para la comunidad médica.
Aclarion (NASDAQ: ACON)은 자사의 Nociscan 제품이 Siemens Healthineers 잡지인 MAGNETOM Flash의 RSNA 에디션에 소개되었다고 발표했습니다. 이 기사는 의사들이 만성 요통 환자 치료에 Nociscan을 어떻게 통합하는지를 보여줍니다. Nociscan은 디스크 통증과 관련된 화학 생체 지표를 정량화하여 의사들이 요추에서 통증이 있는 디스크와 없는 디스크를 비침습적으로 구별하는 데 도움을 주는 최초의 증거 기반 SaaS 플랫폼입니다. 이 기능은 2024년 12월 1일부터 4일까지 열리는 RSNA 연례 회의에서 강조될 예정이며, 의료 커뮤니티에 귀중한 참고 자료가 될 것으로 예상됩니다.
Aclarion (NASDAQ: ACON) a annoncé que son produit Nociscan est présenté dans l'édition RSNA du magazine Siemens Healthineers, MAGNETOM Flash. L'article présente comment les médecins intègrent Nociscan dans leurs pratiques cliniques pour les patients souffrant de douleurs lombaires chroniques. Nociscan est la première plateforme SaaS soutenue par des preuves qui aide les médecins à distinguer de manière non invasive les disques douloureux des disques non douloureux dans la colonne lombaire en quantifiant les biomarqueurs chimiques associés à la douleur discale. Cette fonctionnalité sera mise en avant lors de la réunion annuelle de la RSNA du 1er au 4 décembre 2024, et elle devrait servir de référence précieuse pour la communauté médicale.
Aclarion (NASDAQ: ACON) hat bekannt gegeben, dass sein Produkt Nociscan in der RSNA-Ausgabe des Siemens Healthineers Magazins MAGNETOM Flash vorgestellt wird. Der Artikel zeigt, wie Ärzte Nociscan in ihre klinischen Praktiken für Patienten mit chronischen Rückenschmerzen integrieren. Nociscan ist die erste evidenzbasierte SaaS-Plattform, die Ärzten hilft, schmerzende von schmerzfreien Bandscheiben in der Lendenwirbelsäule nicht-invasiv zu unterscheiden, indem chemische Biomarker quantifiziert werden, die mit Bandscheibenschmerzen assoziiert sind. Das Feature wird bei der RSNA-Jahrestagung vom 1. bis 4. Dezember 2024 hervorgehoben und wird voraussichtlich einen wertvollen Referenzpunkt für die medizinische Gemeinschaft darstellen.
- Featured placement in Siemens' globally distributed MAGNETOM Flash magazine enhances product visibility
- Strategic timing with RSNA annual meeting provides significant exposure to target medical audience
- Product addresses large market opportunity with 266 million people suffering from degenerative spine disease globally
- None.
Insights
The feature of Nociscan in Siemens' MAGNETOM Flash magazine represents incremental progress in market visibility but lacks immediate financial or operational impact. While the publication may help with future adoption among Siemens' customer base, it's primarily a marketing development without tangible near-term business implications.
The chronic low back pain market represents a significant opportunity with 266 million people affected globally, but this article doesn't introduce new clinical data, partnerships, or revenue-generating developments. The publication in a peer-to-peer magazine, while prestigious within the medical community, is not likely to materially affect the company's market position or financial performance in the immediate term.
Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients
MAGNETOM Flash is a Peer-to-Peer Magazine Published by Siemens to Showcase Advancing Technologies in the MRI Space
The RSNA Edition Coincides With the Annual Meeting of the Radiology Society of North America (RSNA)
BROOMFIELD, Colo., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its Nociscan product is featured in the RSNA Edition of Siemens Healthineers magazine, MAGNETOM Flash. The RSNA annual meeting is December 1-4, 2024. The inclusion of Nociscan highlights the challenges of chronic low back pain and illustrates the growing importance of MR spectroscopy (MRS) as an innovative decision support tool for physicians.
“Aclarion is pleased to have Nociscan featured in the 2024 RSNA Edition of MAGNETOM Flash,” said Ryan Bond, Chief Strategy Officer. “We are honored to have renowned physicians like Drs. Eastlack and Jabour illustrate how they utilize Nociscan. We expect this article will be an important feature at the 2024 RSNA meeting and a valuable reference for physicians and clinicians into 2025 and beyond, as the medical community continues adopting enhanced decision support tools, like Nociscan, to solve the low back pain diagnostic dilemma.”
MAGNETOM Flash is the peer-to-peer magazine published by Siemens Healthineers and is available to their customers world-wide. The magazine was created nearly 30 years ago to showcase advancing technologies across the Siemens MR ecosystem, as illustrated by physicians and clinicians for the benefit of their peers. The magazine presents clinical case studies, application tips, technical and product information. The MAGNETOM Flash is available to Siemens customers, qualified physicians, technologists, physicists, and radiology departments.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain.
For a copy of the Nociscan article, please email: info@aclarion.com
To find a Nociscan center, view our site map here.
More information about MAGNETOM Flash, please visit: MAGNETOM Flash
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
FAQ
What is Aclarion's Nociscan featured in the 2024 RSNA Edition of MAGNETOM Flash?
When is the 2024 RSNA annual meeting where Aclarion (ACON) will showcase Nociscan?
How does Aclarion's Nociscan help with chronic low back pain diagnosis?
